ライフサイエンスコーパス: bronchitis

1 isease including COPD (emphysema and chronic bronchitis).

2 IgG (not IgE), and positive GM (Aspergillus bronchitis).

3 g diseases such as asthma, COPD, and chronic bronchitis.

4 f chronic obstructive pulmonary disease, and bronchitis.

5 ay play a role in the development of chronic bronchitis.

6 ough, eczema, and parental history of asthma/bronchitis.

7 ay diseases, including emphysema and chronic bronchitis.

8 meningitis and one in the combined group had bronchitis.

9 ecent use of intravenous corticosteroids for bronchitis.

10 ons seen in chronic otitis media and chronic bronchitis.

11 f chronic obstructive pulmonary disease, and bronchitis.

12 sfunction and acute rejection or lymphocytic bronchitis.

13 tract infections, including otitis media and bronchitis.

14 e respiratory diseases such as pneumonia and bronchitis.

15 no better than low-dose vitamin C for acute bronchitis.

16 ted, FEV(1)/FVC < 90% predicted) and chronic bronchitis.

17 excess of that seen in patients with chronic bronchitis.

18 (LOD = 1.21) and 22 (LOD = 1.37) for chronic bronchitis.

19 es of physician-diagnosed asthma and chronic bronchitis.

20 eas of CD3(+) CD8(+) T cell-rich lymphocytic bronchitis.

21 c fibrosis (CF) causes a chronic destructive bronchitis.

22 pneumonia and acute exacerbations of chronic bronchitis.

23 y airway diseases such as asthma and chronic bronchitis.

24 treatment of adults with uncomplicated acute bronchitis.

25 ions, including otitis media, sinusitis, and bronchitis.

26 ory conditions such as asthma, wheezing, and bronchitis.

27 ranulomatous rhinosinusitis, and aspergillus bronchitis.

28 help improve MCC in smoking-related chronic bronchitis.

29 illosis, chronic pulmonary aspergillosis and bronchitis.

30 ogression that are characteristic of chronic bronchitis.

31 w in primary care and in patients with acute bronchitis.

32 in patients with smoking-associated chronic bronchitis.

33 gm other than when accompanied by a cold, or bronchitis.

34 atic perfusion in most patients with plastic bronchitis.

35 ecreases in subjects with history of chronic bronchitis.

36 rapy in moderate-to-severe COPD with chronic bronchitis.

37 subphenotypes such as emphysema and chronic bronchitis.

38 ith improved outcomes in patients with acute bronchitis?

39 rence from cough variant asthma/eosinophilic bronchitis, 1.1 to 20.1 [p = 0.01]).

40 ng/ml) and cough variant asthma/eosinophilic bronchitis (10.2 ng/ml) than in normal subjects (2.6 ng/

41 s similar in asthma (13.4%) and eosinophilic bronchitis (12.5%).

42 (16 mL/y [95% CI, 12-20 mL/y]), mild wheezy bronchitis (14 mL/y [95% CI, 8-19 mL/y]), wheezy bronchi

43 chitis (14 mL/y [95% CI, 8-19 mL/y]), wheezy bronchitis (16 mL/y [95% CI, 11-20 mL/y]), and persisten

44 ernatant in eight patients with eosinophilic bronchitis, 17 patients with asthma matched for sputum e

45 re significantly more likely to have chronic bronchitis (19.5% versus 6.1%) and emphysema (7.9% versu

46 2.26-4.15; p<0.0001), childhood pneumonia or bronchitis (2.43, 1.44-4.10; p=0.002), parental history

47 rge majority of cases of uncomplicated acute bronchitis.2.

48 II/IV, or protein-losing enteropathy/plastic bronchitis) 20 years after Fontan was 70% (95% CI, 63%-7

49 ts with cough variant asthma or eosinophilic bronchitis, 20 patients with nonasthmatic chronic cough,

50 diagnosed in 71.9% (pneumonia, 42.3%; acute bronchitis, 21.9%; chronic obstructive pulmonary disease

51 (URTIs) (24%), acute sinusitis (24%), acute bronchitis (23%), otitis media (5%), pharyngitis, laryng

52 itions for one or more ARI: pneumonia (537), bronchitis (2931), sinusitis (717) and non-specific ARI

53 RI, including the common cold (53.4%), acute bronchitis (31.3%), acute sinusitis (13.6%), or acute la

54 r respiratory tract infections; 42 [15%] had bronchitis, 34 [12%] had viral upper respiratory tract i

55 7.7%), diarrhea (4.8%), headache (4.8%), and bronchitis (4.8%).

56 t mechanism of the bothersome cough of acute bronchitis.4.

57 42); asthma: 27 +/- 40 pg/ml (n = 11); acute bronchitis: 44 +/- 112 pg/ml (n = 14); pneumonia: 55 +/-

58 age of 50 years was 64% in those with wheezy bronchitis, 47% for those with persistent asthma, and 15

59 antibiotic treatment of uncomplicated acute bronchitis.6.

60 tions of COPD were used: symptoms of chronic bronchitis (667 subjects), physician-diagnosed emphysema

61 for sinusitis (adjusted proportion, 86%) and bronchitis (85%) and varied little according to fever, a

62 or the highest quartile was 0.66 for chronic bronchitis (95 percent confidence interval, 0.52 to 0.85

63 In cystic fibrosis and chronic bronchitis, airways are chronically injured by exposure

64 nd 6.4-fold (1.4, 28) higher in eosinophilic bronchitis and 1.9-fold (1.3, 2.9) and 7.7-fold (1.2, 46

65 cipients with viral infection and transplant bronchitis and again observed excessive epithelial p80 e

66 of vanadium pentoxide (V(2)O(5)) results in bronchitis and airway fibrosis.

67 ficant damage to the lungs with acute, focal bronchitis and alveolitis associated with massive pulmon

68 Childhood wheezy bronchitis and asthma are associated with an increased r

69 pathogen of the conducting airways, causing bronchitis and atypical or "walking" pneumonia in humans

70 less prokaryote Mycoplasma pneumoniae causes bronchitis and atypical pneumonia in humans.

71 Mycoplasma pneumoniae is a major cause of bronchitis and atypical pneumonia in humans.

72 first public hospital admission for asthma, bronchitis and bronchiolitis (International Classificati

73 Daily counts of ED visits for bronchitis and bronchiolitis (n = 80,399), pneumonia (n

74 Co-occurrence of chronic bronchitis and emphysema and/or pneumonia had a stronger

75 -Antitrypsin (AAT) deficiency predisposes to bronchitis and emphysema associated with neutrophilic ai

76 r co-occurring respiratory diseases, chronic bronchitis and emphysema continue to have a positive ass

77 Chronic bronchitis and emphysema were positively associated with

78 e pulmonary disease (COPD) comprises chronic bronchitis and emphysema, and is a leading cause of morb

79 st physician-diagnosed emphysema and chronic bronchitis and low spirometry values.

80 lymphatic imaging, in patients with plastic bronchitis and percutaneous lymphatic intervention as a

81 oniae is a major cause of community-acquired bronchitis and pneumonia in humans.

82 causing otitis media in children and chronic bronchitis and pneumonia in patients with chronic obstru

83 e of otitis media in children and of chronic bronchitis and pneumonia in patients with chronic obstru

84 re frequent causes of repeated common colds, bronchitis and pneumonia, which often occur unpredictabl

85 ne to serious lung infections that result in bronchitis and pneumonia.

86 greater incidences than referents of chronic bronchitis and self- reported asthma and emphysema.

87 Secondary complications such as bronchitis and sinusitis occurred in 15% of placebo reci

88 A history of bronchitis and/or emphysema was recorded from the medica

89 variable combined those with either chronic bronchitis and/or emphysema, together considered as chro

90 onchitic symptoms (chronic cough, phlegm, or bronchitis) and of wheeze in the previous 12 months were

91 7 of 218) had pneumonia, 32% (70 of 218) had bronchitis, and 14% (31 of 218) had colonization; in-hos

92 Is, 53% with acute sinusitis, 62% with acute bronchitis, and 65% with otitis media.

93 vere airflow limitation, symptoms of chronic bronchitis, and a history of exacerbations, whose diseas

94 were respiratory tract infection, headache, bronchitis, and asthma worsening.

95 r those with history of diabetes, emphysema, bronchitis, and asthma, respectively, compared with thos

96 vere airflow limitation, symptoms of chronic bronchitis, and at least two exacerbations in the previo

97 with public hospital admissions for asthma, bronchitis, and bronchiolitis (International Classificat

98 dysfunction on acute rejection, lymphocytic bronchitis, and bronchiolitis obliterans syndrome stage

99 spiratory illnesses (LRI) (croup, pneumonia, bronchitis, and bronchiolitis) in the first year.

100 cute bacterial infections causing sinusitis, bronchitis, and community-acquired pneumonia.

101 independent of acute rejection, lymphocytic bronchitis, and community-acquired respiratory viral inf

102 independent of acute rejection, lymphocytic bronchitis, and community-acquired respiratory viral inf

103 fe, manifests as childhood asthma and wheezy bronchitis, and continues into early adulthood.

104 ibit abnormal MCT, including asthma, chronic bronchitis, and cystic fibrosis.

105 g diseases including asthma, cancer, chronic bronchitis, and cystic fibrosis.

106 piratory diseases, including asthma, chronic bronchitis, and cystic fibrosis.

107 respiratory diseases such as asthma, chronic bronchitis, and emphysema.

108 eart disease, heart failure, cancer, chronic bronchitis, and emphysema.

109 airway fluid (e.g., cystic fibrosis, chronic bronchitis, and exercise-induced asthma).

110 elated phenotypes such as emphysema, chronic bronchitis, and hypoxemia.

111 disease includes both emphysema and chronic bronchitis, and in the case of chronic bronchitis repres

112 ic upper respiratory tract infections, acute bronchitis, and influenza) from 18 months preinterventio

113 or acute sinusitis, acute pharyngitis, acute bronchitis, and nonspecific upper respiratory tract infe

114 y disease genes for asthma, COPD and chronic bronchitis, and occupational lung diseases.

115 such as protein-losing enteropathy, plastic bronchitis, and peripheral edema that may involve the ly

116 of occupational exposures in asthma, chronic bronchitis, and respiratory symptoms in the Singapore Ch

117 Asthma, wheezy bronchitis, and wheezing were ascertained by interview a

118 h childhood asthma; 53 with childhood wheezy bronchitis; and 239 control subjects (of whom 57 develop

119 atasvir-voxilaprevir alone were diarrhea and bronchitis; and with sofosbuvir-velpatasvir-voxilaprevir

120 biomarker and therapeutic target for chronic bronchitis appear to be warranted.

121 opriate antibiotic use for adults with acute bronchitis apply to immunocompetent adults without compl

122 Results for bronchitis are more positive, although intervention tria

123 mia, protein-losing enteropathy, and plastic bronchitis are potential complications of the Fontan cir

124 onia, atypical pneumonia, bronchiolitis, and bronchitis-are responsible for much morbidity and mortal

125 itis, eczema, allergy, emphysema, or chronic bronchitis as diagnosed by a doctor.

126 ce area (emphysema) and airway inflammation (bronchitis) as the consequence of cigarette smoke (CS) e

127 bjects and compared large-airway lymphocytic bronchitis assessed by a 0-2 "E-score" and with standard

128 'Minor' sequelae (chronic bronchitis, asthma, other abnormal pulmonary function, o

129 ncidence of influenza-like illness and acute bronchitis at that time.

130 upper respiratory infection, croup, asthma, bronchitis, bronchiolitis, a wheezy lower respiratory in

131 ry-tract symptoms but, more frequently, with bronchitis, bronchiolitis, and pneumonia.

132 e respiratory tree and can cause tracheitis, bronchitis, bronchiolitis, diffuse alveolar damage with

133 of patients with cystic fibrosis and chronic bronchitis but not in the respective controls.

134 L-12 was also inducible during paramyxoviral bronchitis, but in this case, initial IL-12 p70 expressi

135 ammatory diseases such as asthma and chronic bronchitis, but the mechanisms and consequences of the c

136 s suggest that antibiotic treatment of acute bronchitis can be reduced by using a combination of pati

137 COPD, chronic bronchitis (CB) and active smoking have all been associa

138 Chronic bronchitis (CB) is a common but variable phenomenon in c

139 Chronic bronchitis (CB) is characterized by persistent cough and

140 Rationale: Chronic bronchitis (CB) is characterized by productive cough wit

141 in clinically stable and acutely ill chronic bronchitis (CB) patients.

142 s obstruction and the development of chronic bronchitis (CB).

143 -years of smoking, and asthma, emphysema, or bronchitis (chronic obstructive pulmonary disease) were

144 seen in respiratory disorders (eg, asthma or bronchitis, chronic obstructive pulmonary disease (COPD)

145 nd associated diseases, e.g. asthma, chronic bronchitis, chronic obstructive pulmonary disease, and h

146 (nose, eyes, and throat irritations; cough; bronchitis; cold; wheezing; asthma attacks), medication

147 eloped necrotizing rhinitis, tracheitis, and bronchitis comparable to diacetyl-induced injury.

148 pper respiratory tract infections, and acute bronchitis, conditions that are primarily viral.

149 A history of chronic bronchitis conferred a relative risk of 1.47 (95% CI: 1.

150 E, namely airway hyperresponsiveness (AHR), bronchitis, cough reflex hypersensitivity, damage to the

151 act infection; however, for otitis media and bronchitis, declines were only observed in the populatio

152 Patient satisfaction with care for acute bronchitis depends most on physician-patient communicati

153 It is also used to treat asthma, bronchitis, diarrhea, headache, inflammation and cardiac

154 xposure, atopic diseases), symptoms (chronic bronchitis, dyspnea-modified Medical Research Council sc

155 f nonmalignant respiratory diseases (asthma, bronchitis, emphysema, hay fever, and pneumonia) in 1,55

156 the role of previous lung diseases (chronic bronchitis, emphysema, pneumonia, and tuberculosis) in t

157 ate lung cancer risk associated with chronic bronchitis, emphysema, tuberculosis, pneumonia, and asth

158 al class, physical activity index, prevalent bronchitis/emphysema, and prevalent asthma.

159 ns even in asthma patients with neutrophilic bronchitis, EPX-based ELISA levels are not increased in

160 pper respiratory tract infections, and acute bronchitis (for which routine antibiotic treatment is no

161 Bacterial bronchitis (four patients) and obstructive granulomas (t

162 g chronic cough include asthma, eosinophilic bronchitis, gastro-oesophageal reflux disease, postnasal

163 yperplasia, histological features of chronic bronchitis, have been linked to epidermal growth factor

164 =1.23; 95% CI: 0.97, 1.55) and bronchiolitis/bronchitis (HR=1.13; 95% CI: 0.99, 1.30).

165 Infectious bronchitis (IB) caused by infectious bronchitis virus (I

166 edia in children and exacerbation of chronic bronchitis in adults.

167 s virus is the causative agent of infectious bronchitis in chickens.

168 H1 provides a novel target to reduce chronic bronchitis in COPD patients.

169 inosis, chest tightness at work, and chronic bronchitis in cotton workers.

170 s 1.64 at chromosome 19, whereas for chronic bronchitis in smokers only, the maximum LOD was 2.08 at

171 Eosinophilic bronchitis is a common cause of chronic cough, which lik

172 Pulmonary emphysema, together with chronic bronchitis is a part of chronic obstructive pulmonary di

173 Plastic bronchitis is a potentially fatal disorder occurring in

174 liary clearance associated with mild chronic bronchitis is acutely improved with minimal doses of aer

175 Acute bronchitis is an acute cough illness in otherwise health

176 In conclusion, eosinophilic bronchitis is associated with active airway inflammation

177 onstrated, it is unclear if childhood wheezy bronchitis is associated with COPD.

178 antibiotic treatment of uncomplicated acute bronchitis is not recommended, regardless of duration of

179 value of azithromycin for treatment of acute bronchitis is unknown, even though this drug is commonly

180 ng allografts that contribute to lymphocytic bronchitis (LB) and bronchiolitis obliterans (BO).

181 Lymphocytic bronchitis (LB) precedes CLAD and has a defined molecula

182 ; 95% CI: 1.47-3.65), daily intake of asthma/bronchitis medication (OR = 2.26; 95% CI: 1.42-3.58), fi

183 Daily intake of asthma/bronchitis medication and incidence of asthma, allergic

184 rgic rhinitis, atopic dermatitis, and asthma/bronchitis medication.

185 of UTP in chronic smokers with mild chronic bronchitis (n = 15) by measuring the clearance of (99m)T

186 n = 189,816), and for 0- to 18-year-olds for bronchitis (n = 76,243), chronic sinusitis (n = 15,745),

187 and pleural effusion, postoperative plastic bronchitis, need for transplant, and mortality were tabu

188 ld L) to inhibit the virulence of infectious bronchitis, Newcastle disease, avian influenza, porcine

189 n 137 patients with COPD and 26 with chronic bronchitis (normal spirometry).

190 air pollutants are important determinants of bronchitis occurrence.

191 terval, 3.73-10.94), as was childhood wheezy bronchitis (odd ratio 1.81; 95% confidence interval, 1.1

192 We evaluated lymphocytic bronchitis on endobronchial biopsies as a risk factor fo

193 g toxic effects were hospital admissions for bronchitis (one) and pleural effusion (one), grade 3 inc

194 ve association with lung cancer than chronic bronchitis "only." Asthma had an inverse association wit

195 ins were more likely to cause pneumonia than bronchitis or colonization, respectively.

196 uded a doctor's diagnosis of asthma, chronic bronchitis or COPD, and a history of wheezing or use of

197 14% vs. 10%), while similar rates of chronic bronchitis or emphysema (1% vs. 1%) and asthma (1% vs. 1

198 ng cough or shortness of breath), 2) chronic bronchitis or emphysema, and 3) asthma.

199 nfidence interval (CI): 1.08, 1.30), chronic bronchitis (OR = 1.26, 95% CI: 1.01, 1.57), and adult-on

200 Bronchitis, or airway inflammation, may be predominantly

201 as a diagnosis of pneumonia, bronchiolitis, bronchitis, or bronchial hyperreactivity.

202 Patients were grouped by colonization, bronchitis, or pneumonia and were compared for different

203 e pulmonary diseases (COPDs) such as asthma, bronchitis, or pneumonia.

204 ases, such as asthma, emphysema, and chronic bronchitis, or to alleviate recurrent exacerbations.

205 rence in efficacy by sex, history of chronic bronchitis, oxygen use, or concomitant COPD therapy.

206 ponse by sex (P = 0.75), presence of chronic bronchitis (P = 0.19), concomitant inhaled therapy (P =

207 alue) and with an increased risk of allergic bronchitis (p = 1.77*10(-4) and p = 7.94*10(-4), respect

208 uctive pulmonary disease (PAF, 14%); chronic bronchitis (PAF, 13%); idiopathic pulmonary fibrosis (PA

209 ay quantitate a key component of the chronic bronchitis pathophysiologic cascade that produces sputum

210 ction, in children with protracted bacterial bronchitis (PBB) and mild bronchiectasis (BE).

211 hogen that frequently causes ear infections, bronchitis, pneumonia, and exacerbations in patients wit

212 waterborne pathogen responsible for causing bronchitis, pneumonia, and gastrointestinal infections,

213 Chronic bronchitis, pneumonia, emphysema, and asthma were associ

214 ction impairment, asthma, and a history with bronchitis/pneumonia.

215 nest (44.3%), followed by mixed (30.8%), and bronchitis predominant (25.0%).

216 Data from chronic-bronchitis questionnaires and data on total mucin concen

217 level and increased asthma and bronchiolitis/bronchitis rates in childhood were consistent with a pre

218 of effective vaccines.IMPORTANCE Infectious bronchitis remains a major problem in the global poultry

219 ronic bronchitis, and in the case of chronic bronchitis represents an inflammatory response of the ai

220 owing Medical Subject Headings terms: "acute bronchitis," "respiratory tract infection," "pharyngitis

221 Mouse paramyxoviral bronchitis resulted in airway epithelial cell infection

222 COPD), which comprises emphysema and chronic bronchitis resulting from prolonged exposure to cigarett

223 e fluid secretions in infectious or allergic bronchitis/rhinitis.

224 (RR, 1.15; 95% CI, 1.00-1.32; P = .05), and bronchitis (RR, 1.18; 95% CI, 1.01-1.37; P = .04) at any

225 tions: RR, 1.15; 95% CI, 0.97-1.35; P = .11; bronchitis: RR, 1.20; 95% CI, 1.01-1.43; P = .04).

226 presumptive diagnosis of uncomplicated acute bronchitis should focus on ruling out serious illness, p

227 ng influenza outbreaks, including pneumonia, bronchitis, sinusitis, and otitis media.

228 ed 18-64 years with an ARTI diagnosis (acute bronchitis, sinusitis, pharyngitis, otitis media, allerg

229 tabine, and tenofovir alafenamide group; and bronchitis (six [11%]), vitamin D deficiency (four [7%])

230 (COPD) is a progressive condition of chronic bronchitis, small airway obstruction, and emphysema that

231 ified Medical Research Council >/=2, chronic bronchitis, St. George's Respiratory Questionnaire >25,

232 Information on current bronchitis symptoms and asthma, home environment, and de

233 associations of e-cigarette use with chronic bronchitis symptoms and wheeze in an adolescent populati

234 king, bronchodilator responsiveness, chronic bronchitis symptoms, and index case status.

235 tructive pulmonary disease (COPD)-associated bronchitis than in those from throats of healthy individ

236 on and susceptibility to recurrent infective bronchitis that may, in turn, contribute to further ster

237 In eosinophilic bronchitis the mean concentration of sputum PGD(2) (0.79

238 kage of mild airflow obstruction and chronic bronchitis to several genomic regions; for mild airflow

239 sistent with acute rejection and lymphocytic bronchitis, to subepithelial and intraluminal fibrotic l

240 reatment-related sinusitis, pneumonia, viral bronchitis, tooth infection, stomatitis, and leukopenia

241 five [6%]), pulmonary embolism (three [4%]), bronchitis (two [2%]), atrial fibrillation (two [2%]), a

242 neric term encompasses emphysema and chronic bronchitis, two common conditions, each having distinct

243 ronic obstructive pulmonary disease, chronic bronchitis, two or more exacerbations and/or hospitaliza

244 A sample enriched for asthma and chronic bronchitis underwent a further questionnaire, pre- and p

245 initiate antibiotic therapy in patients with bronchitis unless pneumonia is suspected.

246 er risk of atopic dermatitis and obstructive bronchitis until 3 years.

247 er risk of atopic dermatitis and obstructive bronchitis until age 3 years.

248 investigated its efficacy against infectious bronchitis using a broiler infection model.

249 ensive use of vaccines to control infectious bronchitis virus (IBV) and other poultry pathogens.

250 The gammacoronavirus infectious bronchitis virus (IBV) causes an acute, highly contagiou

251 eral gammacoronaviruses including infectious bronchitis virus (IBV) contain a putative open reading f

252 tein from the group 3 coronavirus infectious bronchitis virus (IBV) contains a canonical dilysine end

253 t signal of the avian coronavirus infectious bronchitis virus (IBV) contains two cis-acting signals e

254 we show that the Gammacoronavirus infectious bronchitis virus (IBV) does induce host shutoff, and we

255 r investigate the function of the infectious bronchitis virus (IBV) E protein, we developed a recombi

256 The E protein from the avian infectious bronchitis virus (IBV) has dramatic effects on the secre

257 in vitro The E protein from avian infectious bronchitis virus (IBV) has dramatic effects on the secre

258 her viruses, the gammacoronavirus infectious bronchitis virus (IBV) has evolved under evolutionary pr

259 Infectious bronchitis virus (IBV) infects ciliated epithelial cells

260 ectious bronchitis (IB) caused by infectious bronchitis virus (IBV) is currently a major threat to ch

261 the E protein of the coronavirus infectious bronchitis virus (IBV) is localized to the Golgi complex

262 n the present study, we show that infectious bronchitis virus (IBV) is resistant to IFN treatment and

263 in the intracellular targeting of infectious bronchitis virus (IBV) membrane proteins.

264 The potential interactome of the infectious bronchitis virus (IBV) N protein was mapped using stable

265 Infectious bronchitis virus (IBV) ORF 3a is one such gene.

266 Like all coronaviruses, avian infectious bronchitis virus (IBV) possesses a long, single-stranded

267 cement using the homologous avian infectious bronchitis virus (IBV) structure.

268 gence of a nephropathogenic avian infectious bronchitis virus (IBV) with a novel genotype in India.

269 ant domains of the N protein from infectious bronchitis virus (IBV), a prototype coronavirus.

270 While infectious bronchitis virus (IBV), a respiratory pathogen of chicke

271 Avian coronaviruses, including infectious bronchitis virus (IBV), are important respiratory pathog

272 he prototypical Gammacoronavirus, infectious bronchitis virus (IBV), induces a delayed activation of

273 strain of avian Gammacoronavirus infectious bronchitis virus (IBV), induces regions of ER that are z

274 mmacoronavirus, including chicken infectious bronchitis virus (IBV), require specific alpha2,3-linked

275 the frameshifting pseudoknot from infectious bronchitis virus (IBV), three constituent hairpins, and

276 y employing the avian coronavirus infectious bronchitis virus (IBV).

277 oplasmic tail of the S protein of infectious bronchitis virus (IBV).

278 n MERS-CoV M and the M protein of infectious bronchitis virus (IBV).

279 th the important poultry pathogen infectious bronchitis virus (IBV).

280 ble to inhibit the early phase of infectious bronchitis virus and Dengue infection, in addition to th

281 aracterization of CoV N NTDs from infectious bronchitis virus and from severe acute respiratory syndr

282 tail for two other coronaviruses, infectious bronchitis virus and the severe acute respiratory syndro

283 erimental data for adenovirus and infectious bronchitis virus infections as examples, we demonstrate

284 spike than that of M41.IMPORTANCE Infectious bronchitis virus is the causative agent of infectious br

285 acid identity similar to that of infectious bronchitis virus N protein and shares a higher level of

286 ellular localization of the avian infectious bronchitis virus N protein both in the absence and in th

287 9N2, Newcastle disease virus, and infectious bronchitis virus were found.

288 V) and SARS-CoV and the gamma-CoV infectious bronchitis virus.

289 Chronic bronchitis was associated with increased frequencies of

290 increased with childhood asthma, and wheezy bronchitis was associated with reduced FEV1 that was evi

291 Prescribing antibiotics for acute bronchitis was associated with reduced overall and night

292 Endobronchial lymphocytic bronchitis was more prevalent in subjects in BOS stage 0

293 exposure to pets, doctor's diagnosed wheezy bronchitis (WB), and compositional changes in the gut mi

294 The occurrence of chest infections, bronchitis, wheeze, and eczema in children was assessed

295 g acute otitis media, sinusitis, and chronic bronchitis, which are preceded by asymptomatic H. influe

296 ic obstructive pulmonary disease and chronic bronchitis who are at risk of frequent and severe exacer

297 rrected congenital heart disease and plastic bronchitis who presented for lymphatic imaging and inter

298 Adults diagnosed with acute bronchitis, without evidence of underlying lung disease,

299 exacerbation, tachypnea, wheezing, worsening bronchitis, worsening dyspnea, influenza, pneumonia, oth

300 cin concentration and a diagnosis of chronic bronchitis yielded areas under the curve of 0.72 (95% co